Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections

-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform- San Diego, California, Aug 14, 2019 – Forge Therapeutics, Inc. (Forge), a ...

Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections2021-03-02T18:28:31-08:00

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting

San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David ...

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting2018-04-09T06:55:22-07:00
Go to Top